Navigation Links
ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
Date:12/18/2007

LEXINGTON, Mass., Dec. 18 /PRNewswire/ -- ActivBiotics, Inc. today announced that following a review of strategic options after its clinical trial of Rifalazil failed in peripheral arterial disease patients, the Company is selling all or substantially all of its assets on an "as is" basis through an Assignment for the Benefit of Creditors, process. The Assignee of the assets is Mr. Joseph Finn, Jr., CPA (see contact details below). The bidding for the assets, which may be purchased separately or in combination, will begin today and end on February 1, 2008. Any person interested in purchasing the assets or learning more about the bidding process should contact the Assignee, Mr. Joseph Finn, Jr.

"The Board of Directors has decided to pursue the sale of the company's clinical and preclinical drug assets," said Steven C. Gilman, Ph.D., Chairman of ActivBiotics. "We believe that our anti-inflammatory Phase II drug candidate and our antibacterial library of compounds are of significant value to companies in those therapeutic areas," added Gilman. Bidding packages have been assembled and are ready to be distributed subject to a potential purchaser entering into a standard form confidentiality agreement.

The Company assets available for sale include:

1. A superoxide dismutase (SOD) mimetic program consisting of two clinical-stage drug candidates, M40403 and M40419, and a library of 250 small molecules which have potential as novel therapeutic agents for the treatment of inflammatory diseases. M40403, which has been studied in approximately 700 patients/subjects, has an active IND, and a protocol on file with the FDA under which a Phase II clinical trial for the treatment of post-operative ileus can be conducted, and a protocol to initiate a Phase II clinical trial for the treatment of oral mucositis. The Company has submitted and expects to shortly receive Orphan Drug Designation status in Europe and has an Orphan Drug application pending with th
'/>"/>

SOURCE ActivBiotics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
2. Exelixis Sells 80% Stake in Artemis to Taconic
3. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
4. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
5. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
6. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
7. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
8. AMDLs Jade Pharmaceutical Subsidiary Announces New Product Strategy; Six New Products, Including One With Sales Projected at Upwards of $10 Million, Under Development
9. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
10. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
11. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
(Date:5/23/2013)... May 23, 2013 Pusan National University ... private biotherapeutics and contract research company focused on ... cancer, announced today a publication reporting the induction ... the oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; ... published in the May 15 th , 2013 ...
(Date:5/23/2013)... Louis, Missouri (PRWEB) May 23, 2013 ... and manufacture of complete thermal systems, recently introduced ... than 90 years of experience in designing and ... complete selection of products to serve diverse customer ... options is featured at the beginning of the ...
(Date:5/22/2013)... iLuv Creative Technology, the premier provider ... mobile lifestyle, announces they are now shipping MultiCharger-X, an ... iPad devices efficiently. Winner of the 2013 internationally recognized ... award, MultiCharger-X is revolutionizing the way businesses, schools, and ... , MultiCharger-X (iAD910) combines the best ...
Breaking Biology Technology:NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Watlow Introduces Its New Industrial Heater Catalog 2iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3
... NEW ODOR ELIMINATOR, WHAT ODOR?® Signature pitchman, Billy Mays ENDORSES AND ... ... For The Earth Corp is pleased to announce the launch of a ... marketer Billy Mays., , , , ,Nelson Grist, Founder and CEO of ...
... DIEGO, March 2 BioMed Realty Trust, Inc. (NYSE: ... its executive management will present at the Citi 2009 ... 9:05 a.m. Eastern Standard Time on Wednesday, March 4, ... calling 719.785.5595 and providing the passcode 348395. About BioMed ...
... to Revolutionize Food Processing, Industry,VANCOUVER, ... ("EnWave" or "the Company") today announced that it ... nutraREV(TM) food dehydration equipment to CAL-SAN Enterprises, Ltd. ... blueberry producers. With this sale, EnWave has proven ...
Cached Biology Technology:Billy Mays Endorses New Odor Eliminating Product, What Odor? 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4
(Date:5/23/2013)... for the overall health, development, and academic success ... in ensuring that all students have opportunities to ... of vigorous or moderate-intensity physical activity, says a ... Recent estimates suggest that only about half of ... better health and development. The report recommends ...
(Date:5/23/2013)... succeeded in treating cerebral palsy with autologous cord blood. ... 2.5 year old boy had been in a persistent ... two months after treatment with the cord blood containing ... months, the child learned to speak simple sentences and ... Korean study, dispel the long-held doubts about the effectiveness ...
(Date:5/23/2013)... team reveal the interplay of brain chemicals which help ... Trust and BBSRC. , By changing the way ... abilities. While these changes can affect the strength of ... of that response. , Lead author Alex ... with others, you can make yourself better heard by ...
Breaking Biology News(10 mins):Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... role in the brain's ability to monitor body fat content ... diabetes, according to a new report in the August issue ... particular variants of the protein SH2-B might underlie obesity in ... in cells throughout the body, keeps the brain sensitive to ...
... Institute (BGI) of the Chinese Academy of Sciences (CAS) ... (DCPBP) jointly announce the public release of pig genomic ... of the genomes of five different domestic pig breeds ... the first large scale pig genome sequencing effort, the ...
... methods helped public health officials control and limit the ... virus in 2003 related to the consumption of green ... October 15 issue of The Journal of Infectious Diseases, ... Joseph J. Amon, PhD, MSPH, and colleagues at the ...
Cached Biology News:Weight control protein may yield antiobesity drugs 2Weight control protein may yield antiobesity drugs 3‘Blue Brain?project explores thought at molecular level 2Large-scale Computer Simulations Reveal New Insights Into Antibiotic Resistance 2
Monoclonal antibodies conjugated with rhodamine...
... lightweight, the Moticam 2300 camera (MC2300) attaches ... eyetube, or trinocular port. Included in the ... Images 2.0ML software offers quick and accurate ... maximize resolution for examination or documentation purposes. ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... BSA-Free Stabilizer is a bovine protein-free ... It is an aqueous solution that ... MOPS buffer (3-(N-Morpholino) propanesulfonic acid), pH ... combination of 0.02% methylisothiazolone and 0.02% ...
Biology Products: